Akzo Nobel's new business Nobilon has started operating
Nobilon will develop, produce and market human vaccines -- Diosynth, Intervet and Oregon are expected to give support
A new biotech company set up by Akzo Nobel to develop, produce and market human vaccines has started operating in a state-of-the facility located in the Netherlands.
Nobilon will call upon the expertise of the company's three pharmaceutical businesses-Diosynth, Intervet and Organon-with plans to have the first vaccines on the market before the end of the decade.
Intervet-the world's number one producer of animal vaccines-will bring its research know-how and technological expertise in vaccines to the venture, while Organon has extensive knowledge and experience in the development and marketing of human pharmaceutical products. Diosynth's contribution will stem from its experience in the field of production and purification of active pharmaceutical ingredients.
"We aim to have the first human vaccines on the market in 2009," explained Adriaan van Loon, Nobilon's business manager.
"In the first instance we want to introduce a human influenza vaccine and our aim is to produce the first clinical batch for phase I by the end of 2004."
Located next to the existing Intervet site in Boxmeer and built with a sophisticated air treatment system, staff moved into the new state-of-the-art facility in May.
The official opening is planned for November, when all systems should be online.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
